Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2 A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING CLINICAL TRIAL TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF nC-001 IN PATIENTS WITH CHRONIC EUVOLEMIC HYPONATREMIA
CHRONIC EUVOLEMIC HYPONATREMIA
100 Clinical Results associated with nephcentric Inc.
0 Patents (Medical) associated with nephcentric Inc.
100 Deals associated with nephcentric Inc.
100 Translational Medicine associated with nephcentric Inc.